2012-2020年特定地理区域内腹主动脉瘤破裂的治疗——治疗模式的转变
该回顾性研究纳入2012-2020年赫尔辛基大学医院诊断的263例腹主动脉瘤破裂患者,按治疗方式分为rEVAR组(n=119)和rOR组(n=119)。rEVAR组30天生存率83.2% vs rOR组68.9%(P=0.015),90天生存率80.7% vs 67.2%(P=0.026),1年生存率74.8% vs 64.7%(P=0.120)。作者认为rEVAR可作为多数患者的一线治疗选择。
要点
- rEVAR组30天生存率83.2%,rOR组68.9%(P=0.015)。
- rEVAR组90天生存率80.7%,rOR组67.2%(P=0.026)。
- 2018-2020年队列30天、90天、1年生存率分别为84%、81%、77%,高于2012-2014年队列的74%、72%、70%。
核心结论
- rEVAR可作为多数腹主动脉瘤破裂患者的一线治疗选择,与rOR相比可降低短期和中期(至少至1年随访)死亡率。
- 专职血管外科医生实施rEVAR及手术室人员持续模拟培训是低拒绝率和成功治疗rAAA的关键要素。
- 使用封堵性主动脉球囊可降低两种手术方式的总体死亡率。
研究设计与样本
- 回顾性研究,纳入2012-2020年赫尔辛基大学医院诊断的腹主动脉瘤破裂患者共263例。
- 患者按治疗方式分为rEVAR组(n=119)和rOR组(n=119),拒绝治疗率为9.5%(n=25)。
- 主要终点为30天死亡率,次要终点为90天死亡率、1年死亡率和重症监护住院时间。
主要发现
- 30天短期生存率rEVAR组83.2% vs rOR组68.9%(P=0.015)。
- 出院后90天生存率rEVAR组80.7% vs rOR组67.2%(P=0.026)。
- 1年生存率rEVAR组74.8% vs rOR组64.7%(P=0.120)。
- 比较2012-2014年队列与2018-2020年队列,晚期队列30天、90天、1年生存率分别为84%、81%、77%,早期队列分别为74%、72%、70%。
临床怎么用
- 作者认为rEVAR可作为多数腹主动脉瘤破裂患者的一线治疗选择。
- 作者认为专职血管外科医生实施rEVAR和手术室人员持续模拟培训是低拒绝率和成功治疗rAAA的关键要素。
- 作者认为使用封堵性主动脉球囊可降低两种手术方式的总体死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of abdominal aortic aneurysm ruptures (rAAA) has changed from open to endovascular repair (rEVAR) during the last decade. The immediate survival benefit after endovascular treatment method is well-known, yet without conclusive support from randomized controlled studies. The aim of this study is to report the survival benefit of rEVAR during the transition between 2 treatment methods and to highlight the in-hospital protocol for rAAA patients, with continuous simulation training and a designated team. METHODS: This study is a retrospective review of rAAA patients diagnosed at Helsinki University Hospital during 2012-2020, including a total of 263 patients. Patients were divided by treatment method, and the primary end point was 30-day mortality. The secondary end points were 90-days mortality, one year mortality, and the length of stay in intensive care. RESULTS: Patients were divided into the rEVAR group (n = 119) and open repair group (rOR n = 119). The turndown rate was 9.5% (n = 25). The 30-day short-term survival favored endovascular treatment (rEVAR 83.2% vs. rOR 68.9%, P = 0.015). The 90-day postdischarge survival was higher in the rEVAR group (rEVAR 80.7% vs. rOR 67.2%, P = 0.026). One-year survival was also higher in the rEVAR group, however with less statistical significance (rEVAR 74.8% vs. rOR 64.7%, P = 0.120). The effect of the revised rAAA protocol was seen in improved survival, when comparing the first 3 years of the cohort (2012-2014) to the last 3 years of the cohort (2018-2020). Survival rates were higher at 30 days, 90 days, and one year in the late cohort (74% vs. 84%, 72% vs. 81%, and 70% vs. 77%). CONCLUSIONS: The rEVAR has its place as a first-line treatment option for most patients and reduces short-term and midterm mortality at least to 1-year follow-up compared to rOR. Dedicated vascular surgeons for rEVAR and continuous simulation training for the operating room staff are key elements of a low turndown and successful rAAA treatment. The use of an occlusive aortic balloon reduces overall mortality in both operative methods.
引用
- Viitala H, Laukontaus S, Aho P, et al. Treatment of Abdominal Aortic Aneurysm Ruptures in a Well-defined Geographical Area during 2012-2020-A Paradigm Shift. Ann Vasc Surg. 2023. PMID: 37023921. doi:10.1016/j.avsg.2023.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。